Hamilton Lane Advisors’s Vaxcyte PCVX Stock Holding History

Hamilton Lane Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,091	Closed	-$242K	–	78
2020 Q4	$242K	Buy	+9,091	New	+$338K	0.09%	48

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hamilton Lane Advisors's PCVX Position: Q1 2021 in Review

Hamilton Lane Advisors sold out of Vaxcyte (PCVX) in Q1 2021, closing a stake of 9,091 shares — an estimated $242K sold.

Hamilton Lane Advisors first reported a position in PCVX in Q4 2020 and held it in 1 quarter. The position peaked at $242K in Q4 2020. 74 funds tracked by Wall St. Rank hold PCVX as of Q1 2021.

Hamilton Lane Advisors reported no remaining Vaxcyte position as of Q1 2021 after selling out during the quarter.
Hamilton Lane Advisors sold 9,091 Vaxcyte shares in Q1 2021, an estimated $242K.
Hamilton Lane Advisors first reported a position in Vaxcyte in Q4 2020 and held it in 1 quarter.
Hamilton Lane Advisors's Vaxcyte position peaked at $242K in Q4 2020.
74 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2021.

Based on Hamilton Lane Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.